Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)-Reference-Cited by-同舟云学术

Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®)

Published:2023-10-10 Issue: Volume: Page:
ISSN:2768-6566
Container-title:JEADV Clinical Practice
language:en
Short-container-title:JEADV Clinical Practice

Author:

Rinnooy Kan Charlotte E.¹^ORCID,Röckmann Heike²,van Dijk Marijke R.³,Ramsaransing Tanuja¹,Reubsaet Lieke L.⁴,Peters Elke E. M.⁵,Vos Lydia E.¹^ORCID

Affiliation:

1. Department of Dermatology Haaglanden Medical Center The Hague The Netherlands

2. Department of Dermatology University Medical Center Utrecht The Netherlands

3. Department of Pathology University Medical Center Utrecht The Netherlands

4. Department of Medical Microbiology Haaglanden Medical Center The Hague The Netherlands

5. Department of Pathology Haaglanden Medical Center The Hague The Netherlands

Abstract

AbstractBullous cutaneous reactions can be caused by many factors, including vaccines.1 However, among all cutaneous reactions following coronavirus disease 2019 (COVID‐19) mRNA vaccines, bullous reactions are rare. Here, we describe two patients with delayed generalised bullous cutaneous reactions 7 days after receiving  Moderna (Spikevax®) and Pfizer–BioNTech (Comirnaty®) COVID‐19 vaccination, respectively.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jvc2.273

Reference11 articles.

1. The pathogenesis of bullous skin diseases

2. COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

3. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases

4. Cutaneous reactions after SARS‐CoV‐2 vaccination: a cross‐sectional Spanish nationwide study of 405 cases*

5. SARS‐CoV ‐2 vaccine‐related cutaneous manifestations: a systematic review